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Abstract
Objective
NIPT for fetal aneuploidy by digital PCR has been hampered by the large number of PCR
reactions needed to meet statistical requirements, preventing clinical application. Here, we
designed an octoplex droplet digital PCR (ddPCR) assay which allows increasing the num-
ber of available targets and thus overcomes statistical obstacles.
Method
After technical optimization of the multiplex PCR on mixtures of trisomic and euploid DNA,
we performed a validation study on samples of plasma DNA from 213 pregnant women.
Molecular counting of circulating cell-free DNA was performed using a mix of hydrolysis
probes targeting chromosome 21 and a reference chromosome.
Results
The results of our validation experiments showed that ddPCR detected trisomy 21 even
when the sample’s trisomic DNA content is as low as 5%. In a validation study of plasma
samples from 213 pregnant women, ddPCR discriminated clearly between the trisomy 21
and the euploidy groups.
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Conclusion
Our results demonstrate that digital PCR can meet the requirements for non-invasive prena-
tal testing of trisomy 21. This approach is technically simple, relatively cheap, easy to imple-
ment in a diagnostic setting and compatible with ethical concerns regarding access to
nucleotide sequence information. These advantages make it a potential technique of choice
for population-wide screening for trisomy 21 in pregnant women.
Introduction
Screening for trisomy 21 is still mostly based on a risk estimation derived from the measure-
ment of (i) biochemical markers in maternal blood and (ii) first trimester nuchal translucency.
However, the high proportion of false positives in this screening test involves that invasive
sampling (amniocentesis or chorionic villi sampling to obtain a fetal karyotype) is often per-
formed for normal fetuses. Furthermore, those invasive procedures are associated with a 0.2–
0.5% risk of induced miscarriages [1]. Hence, researchers worldwide have long been seeking to
design a more efficient test.
Since the discovery of the existence of circulating cell-free fetal DNA [2], several approaches
have been used to deduce the number of fetal chromosomes on the basis of the DNA circulat-
ing in maternal plasma (despite the fact that the vast majority of DNA in the sample is mater-
nal). To date, only molecule-counting based technologies relying on massively parallel
sequencing (MPS) [3], or microarray-based method (MBM) [4] have yielded a useful screening
tool. Even though MPS and MBM are able to address the problem from a technical point of
view, it is unclear whether it will be applicable to large-scale (population-wide) screening of
pregnant women: the technique is time-consuming, relatively costly and difficult to implement
in genetic testing laboratories and is also hampered by ethical issues [5–8].
In digital PCR (dPCR), endpoint PCR is performed after the sample has been partitioned
into thousands of individual reactors that (on average) contain a single molecule. It then
becomes possible to evaluate the absolute quantification of the input DNA by counting the
number of positive PCRs. Relative to conventional real-time PCR techniques, individual PCRs
provide greater precision and resolution for detecting small concentration differences. The
principle of dPCR was first described in 1999 [9]. However, the application of this technique to
the field of non-invasive prenatal diagnosis of aneuploidies has been impaired by statistical
issues and time-consuming practical issues. Given that cell free fetal DNA accounts for a weak
proportion of the total cell-free DNA in maternal plasma, one needs to count thousands of
molecules (i.e. positive PCRs) in order to reliability detect molecules originating from the triso-
mic chromosome. The lower the proportion of fetal DNA is, the higher the number of positive
PCRs are required [10]. Lastly, given that the amounts of circulating cell-free fetal DNA in the
plasma are very low, a large total number of PCRs have to be performed in order to achieve the
requisite number of positive PCRs.
To date, the two main obstacles to the wider application of dPCR are (i) the technical diffi-
culty of performing several thousands of PCRs, and (ii) the high number of positive PCRs
required for statistical robustness. The first problem has been solved by recent technical break-
throughs in dPCR, such as droplet digital PCR (ddPCR), in which thousands of individual
PCRs are performed in the same reaction well [11,12], which simplifies laboratory workflow.
However, the number of positive PCRs is directly correlated with the number of available target
DNAmolecules in the sample, which is biologically limited. Hence, dPCR-based non-invasive
prenatal testing (NIPT) for trisomy 21 has not previously been developed. Here, we designed a
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technical solution to this problem and tested it on plasma DNA samples from pregnant
women, in order to establish whether our dPCR technique reliably discriminates between
euploid samples and trisomic fetuses.
Materials and Methods
Patient recruitment
In this prospective study, we recruited pregnant women at high risk of chromosomal abnor-
malities and for whom invasive prenatal diagnosis was indicated on the basis of abnormal bio-
chemical and/or ultrasound results. For all pregnancies, fetal karyotypes were available for final
comparison with digital PCR results. The investigators performing the digital PCR experiments
were not aware of the karyotype result. All patients gave their written, informed consent to par-
ticipation in the study. Blood samples were collected (in EDTA tubes) either before the invasive
prenatal diagnosis or at least two weeks afterwards. The study was approved by the local inves-
tigational review board (Comité de protection des personnes Ile de France XI) with the study
approval reference 12079.
The median (range) age of gestation was 16 (9 to 37) weeks. Eighty eight samples (almost
42% of included samples) were obtained during the first trimester of pregnancy (until 14 weeks
of gestation). Patients were addressed for high maternal serum markers (35% of cases), ultra-
sound abnormalities (45%), both anomalies (14%), familial history (3.5%) or other indications
(3.5%).
Sample processing and DNA extraction
One or two 4 ml EDTA tubes were collected for each patient, yielding an average of around 3
ml of plasma per patient. Blood samples were processed within two hours of collection. A
three-step centrifugation protocol was set up for plasma recovery, with centrifugation (i) at 800
g for 10 min, (ii) at 1600 g for 10 min and (iii) at 16000 g for 10 min. Circulating DNA was
extracted using the QIAampTM Circulating Nucleic Acid Kit (QIAGEN, Valencia, CA, USA),
according to the manufacturer's instructions and resuspended in a final volume of 100 μl. The
extracted DNA was stored below -20°C until processing.
Droplet digital PCR
By generating uniform water-in-oil droplets, ddPCR partitions the target sequences into
approximately 15,000 individual “nanoreactors” in the same well. Following an endpoint PCR
using hydrolysis probes, each droplet is read and counted as positive or negative, depending on
the presence or absence of target DNA sequence. It takes about an hour to prepare the droplets
(including mix preparation), two hours for endpoint PCR and less than two minutes per reac-
tion well for fluorescence reading. Absolute quantification is based on the number of positive
droplets and Poisson sampling statistics, as follows: λ = -ln(1-k/n) where k is the number of
positive droplets, n the total number of droplets and λ the mean copies per droplet.
We used the QX100 Droplet Digital PCR system (Bio-Rad Laboratories, Hercules, CA,
USA). We designed a two-color octoplex PCR experiment that overcomes limitations on the
amount of DNA by increasing the number of targets and thus increasing the number of posi-
tive PCRs. We used a set of four FAM TaqMan1 hydrolysis assays for the BRWD1, LTN1,
NCAM2 and RUNX1 genes (Assays identities respectively: Hs03026207_cn, Hs02872951_cn,
Hs05556211_cn, Hs05550012_cn; Life Technologies, Carlsbad, CA, US) to detect chromosome
21. In order to open the field to the screening of both trisomy 21 and 18 at the same time, con-
sidering that the trisomy 18 is the second most frequent trisomy sometimes not identified with
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ultrasound during the 1st or 2nd trimester screening without increasing the final assay price,
we designed a set of four VIC TaqMan1 hydrolysis assays for the CTIF, RIT2, SMAD4 and
TCF4 genes (Assays identities respectively: Hs06500717_cn, Hs06453395_cn, Hs06447834_cn,
Hs00372815_cn; Life Technologies) to detect chromosome 18, which served as a reference
chromosome. The chromosome ratio was calculated by dividing the amount of chromosome
21 by that of the reference chromosome.
However, to demonstrate that concept works whatever the chromosome chosen as a refer-
ence, we also validated our multiplex PCR system using chromosome 1 instead of chromosome
18 as the reference chromosome (S3 Table).
We first tested our multiplex design on serial dilutions of genomic DNA and artificial mix-
tures of trisomic and euploid DNA. Next, we established whether the multiplex assay was able
to reliably discriminate between euploid and trisomic fetuses in plasma samples from pregnant
women at high risk of chromosomal anomalies (according to biochemical and/or ultrasound
screening) for whom a fetal karyotype was available.
Validation of the multiplex PCR
We performed ddPCR on a series of dilutions of genomic DNA from peripheral lymphocytes
using one, two, three or four TaqMan1 assays per chromosome. In a final 20 μL reaction vol-
ume, we mixed 10 μL of 2X ddPCR Supermix for probes (Bio-Rad Laboratories, Inc.) with
0.5 μL of each TaqMan1 assay (the final primers concentration was 450 nM and the final
probes concentration was 125 nM), 2 μL of DNA and water up to 20 μL. The serial dilutions
contained 2, 1, 0.5 and 0.25 ng/μL of DNA. Next, we tested the multiplex PCR assay's sensitiv-
ity for detecting small variations in the chromosome ratio in a very-low-concentration sample
using artificial mixtures of trisomy 21 DNA and euploid DNA. We generated 0.5 ng/μL DNA
mixtures containing 50%, 25%, 10%, 5% or 0% of trisomy 21 DNA. The 0% trisomy 21 sample
was generated using a mix of 10% of one preparation of normal DNA and 90% of another
preparation of normal DNA.
ddPCR with circulating cell-free DNA
We composed a 20 μL reaction mix using 10 μL of 2X ddPCR Supermix for probes, 4 μL of an
equimolar mix of the eight TaqMan1 assays and 6 μL of plasma DNA. Next, we generated
water-in-oil droplets using a commercial droplet generator (Bio-Rad Laboratories, Inc.). Eight
replicates were performed for each sample. The PCR conditions were as follows: 95°C for 10
min, 40 cycles of 94°C for 30 sec and 60°C for 1 min, and then final extension at 98°C for 10
min. The fluorescence signal was measured and analyzed using a QX100 droplet reader and
QuantaSoft software (both from Bio-Rad Laboratories, Inc.). A second run of 2 to 8 replicates
was performed for samples with less than 5900 positive PCRs for the reference chromosome.
Lastly, the chromosome ratio (based on Poisson statistics) was computed using the results of
both runs. In this proof of concept study, we validated the PCR system only on samples from
pregnancies with trisomy 21 or normal fetal karyotype.
Data analysis
Validation of the multiplex PCR. Slopes for the concentrations (according to the dilu-
tion) were computed as a function of the number of probes used in the tested probe sets, and
simultaneous confidence intervals for the slope ratios were computed and compared with
those of the reference slope obtained with one probe for each chromosome [13].
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For artificial mixtures of trisomic and euploid DNA, we performed local polynomial
smoothing of the plot for observed and theoretical chromosome ratios with 95% confidence
intervals, and then compared the observed curve with the expected curve.
ddPCR using circulating cell-free DNA. Chromosome ratios obtained from plasma
DNA in euploid and trisomic groups were compared in a Wilcoxon rank-sum test. A ROC
curve was then plotted.
Results
Validation of the multiplex PCR
Linearity regarding the number of probes in the reaction mix. We used series dilutions
of genomic DNA (2.0, 1.0, 0.5 and 0.25 ng/μL) to validate the correlation between the expected
and observed DNA concentrations for the different probe sets used in the reaction mix. For
each set of n probes, we plotted the concentration curve of the series dilution (Fig 1) and calcu-
lated the slope. Then, we normalized the slopes results by dividing the slopes obtained with 2, 3
and 4 FAM or VIC probes targeting the same chromosome by the slope obtained with a single
probe (FAM or VIC respectively) (Table 1). By this normalization, the slopes ratio should be
equal to the number of probes used to target the same chromosome and this was the case with
our results (Table 1). The slopes ratio when using two or three FAM probes for instance was
respectively 2.05 and 3.22. Moreover, for a given fluorophore, positive droplets remained
clearly distinguishable from negative droplets even when multiplexing the eight probes (see S1
Fig). Taken as a whole, these results demonstrate that our probes did not interfere with each
other.
Linearity regarding the percentage of trisomy 21. We next sought to assess the extent to
which this PCR system was able to detect the small increment in chromosome ratio in trisomy
21 situations in samples mimicking plasma DNA from pregnant women. Given that this DNA
is characterized by a low concentration of fetal DNA and a mix of maternal and fetal DNA, we
created a model of mosaic trisomy by mixing DNA from euploid lymphocytes with DNA from
trisomy 21 lymphocytes at very low concentrations and variable proportions of trisomy 21.
After performing the ddPCR with our validated octoplex design, we compared the obtained
chromosome ratios with the expected ratios. The theoretical ratio, depending on the fetal frac-
tion, was calculated as follows:
r21/ref = [(n21fetal x p) + (n21maternal x (1-p))] / [(nreffetal x p) + (nrefmaternal x
(1-p))], where p is the fetal fraction, n21 is the number of chromosomes 21 from maternal
(n21maternal) or fetal (n21fetal) origin, and nref is the number of reference chromosome per
diploid genome from maternal or fetal origin. The total number of molecules from a chromo-
some of interest being the addition of those from the fetus at a proportion of (p) and those
from the mother at a proportion of (1-p).
In case of an euploid fetus, the theoretical ratio r21/ref is 1. In case of a trisomic fetus for
chromosome 21 and a 10% fetal fraction (p = 0.1), the theoretical ratio can be calculated as
r21/ref = 1 + p/2. = 1.05.
We tested our multiplex assay with artificial mixtures of 0.5 ng/μL DNA (containing 50%,
25%, 10%, 5% or 0% of trisomy 21 DNA) and analyzed the chromosome ratios obtained for
different replicates of the same point. Then, we analyzed the correlation between the observed
ratios and the theoretical ones. When the correlation data were fitted to a linear model (black
solid curve with the confidence interval in black dashed curves, in Fig 2), the estimated inter-
cept and slope [95%CI] were respectively 0.06 [-0.07 to 0.19] and 0.94 [0.82 to 1.05] for theo-
retical values of 0 and 1 (solid gray curve in Fig 2), indicating that experimental ratios are not
significantly different from theoretical ratios Similar results were obtained using mixtures of
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artificially degraded DNA samples (S2 Fig and S1 Table). Furthermore, these results show that
the experimental ratios are similar to the theoretical ratios, but nevertheless not the same.
Validation with clinical samples. After validating the multiplex ddPCR design with geno-
mic DNA samples, we tested it with plasma DNA samples from 213 pregnant women at high
risk of chromosomal anomalies (according to biochemical and/or ultrasound screening). The
fetal karyotype was normal in 192 cases and revealed trisomy 21 in 21 cases. For each sample,
the pregnancy term at blood draw, the fetal karyotype and the results of ddPCR (according to
Fig 1. Validation of the multiplex PCR–serial dilutions for each set of probes. A: FAM probes
(chromosome 21), B: VIC probes (reference chromosome).
doi:10.1371/journal.pone.0155009.g001
Digital PCR as a Non-Invasive Prenatal Test for Trisomy 21
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the Minimum Information for Publication of Quantitative Digital PCR Experiments guidelines
[14]) are shown in S2 Table.
Eight to sixteen replicates were performed for each sample. Approximately 10,000 to 18,000
water-in-oil droplets were generated per replicate, with an average of around 122,000 total
droplets per sample. The median (range) total number of positive PCRs obtained for the refer-
ence chromosome was 13583 (1424 to 85214). We estimated the number of positive PCRs that
had to be obtained to detect a small increase in the number of chromosome 21 molecules (com-
pared with reference chromosome molecules) in cases of trisomy 21 with a low fetal fraction
(10% and 5%). k21 and kref are the number of positive droplets for chromosome 21 and the ref-
erence chromosome, respectively, and n is the total number of PCRs (with about 256,000 PCRs
for samples with sixteen replicates, which is the maximum number here). Although k21 and kref
follow a binomial distribution, they can be considered as having a Gaussian distribution in the
present context. For a single-sided test and with a 97.5% confidence interval, n21 is higher than
nref when k21> kref + 1.96sigma_ref (where sigma_ref =
p
(nkref/n(1-kref/n)). This condi-
tion is met when kref is 1600 (for a fetal fraction of 10%) or 5900 (for a fetal fraction of 5%).
For nine of the samples in our series (samples 1, 9, 40, 64, 66, 67, 76, 84 and 86)the number
of positive PCRs was below 5900 (despite a second run). These quality control failures were
excluded from further analysis (Fig 3).
The distribution of the chromosome ratio in trisomy 21 group was significantly shifted
toward higher values, when compared with the euploid group (p<< 0.0001) (Fig 3). A receiver
operating characteristic (ROC) curve of the chromosome ratio was plotted as a predictor of tri-
somy 21 (Fig 3). The area under the ROC curve (AUROC: 0.951 (CI95%: 0.861;>0.999)) and
the shape of the curve are characteristic of a very good screening test. Similar results were
obtained when considering only 1st trimester samples with more than 5900 positive PCRs
(n = 85, p<< 0.0001); AUROC: 0.920 (95%IC: 0.763;>0.999) (S3 Fig).
According to the ROC curve analysis, the best threshold for distinguishing between Trisomy
21 group and euploidy group is 1.057 (98% of specificity and 94% of sensitivity). With this
threshold, the ratio of sample 41 is a false negative (fetal karyotype was 47,XY,+21). We sought
to quantify the fetal fraction using a duplex hydrolysis probe assays targeting SRY (FAM) and
RNaseP (VIC). None of the approximately 30,000 droplets was SRY-positive, demonstrating an
undetectable fetal fraction. On the other hand, three results can be considered as false positive
(samples 12, 51 and 145).
Table 1. Validation of the multiplex PCR.
Slope (95%CI) R2 Ratio of slopes (95%CI)
FAM
1 probe 31.3 (26.7 to 35.8) 0.998 -
2 probes 64.2 (59.6 to 68.7) 0.994 2.05 (1.77 to 2.43)
3 probes 100.5 (96.0 to 105.0) 0.997 3.22 (2.78 to 3.80)
4 probes 142.0 (137.5 to 146.5) >0.999 4.54 (3.93 to 5.38)
VIC
1 probe 33.2 (28.2 to 38.2) 0.999 -
2 probes 64.1 (59.0 to 69.1) 0.995 1.93 (1.65 to 2.31)
3 probes 101.8 (96.7 to 106.8) 0.994 3.07 (2.64 to 3.68)
4 probes 142.2 (137.2 to 147.2) >0.999 4.29 (3.69 to 5.13)
Ratio of slopes of the concentrations obtained for the multiplex assays in comparison to the simplex assay
(the reference), and simultaneous conﬁdence intervals.
doi:10.1371/journal.pone.0155009.t001
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Among the nine samples excluded for insufficient number of positive PCRs, four were triso-
mic 21 (samples 1, 66, 67 and 76). Except for sample 66 with the lowest number of positive
PCRs (~2800 far from the 5900 required for distinguishing between trisomic and euploid situa-
tions), for three other samples the chromosomal ratio was in favor of a trisomy 21.
Using chromosome 1 as the reference chromosome we tested some plasma DNA samples
(n = 20 among which 3 trisomy 21). Ratio for trisomy 21 (n = 3) and euploid fetus (n = 17)
were respectively at 1.10 and 1.02 (p = 0.007) (S3 Table)
Discussion
In the present study, we developed a novel ddPCR-based method for the non-invasive prenatal
screening of trisomy 21 using DNA from maternal plasma.
Digital PCR has already been proposed as an alternative technique for aneuploidy NIPT.
Fan et al. showed that this approach is precise enough to detect small variation in the chromo-
some ratio caused by trisomy [15, 16]. Firstly, calculations showed that thousands of positive
partitions (the droplets, in ddPCR) were needed to achieve statistical significance with high
confidence, meaning that thousands of PCRs need to be processed [15, 16]. Secondly, and
despite great technical progress in the field of dPCR (enabling thousands of PCRs to be per-
formed in the same well), the number of available target DNAs is sometimes insufficient. By
targeting several genes on the same chromosome with a multiplex of probes labeled with the
same fluorophore, we overcame this limitation by substantially increasing the number of posi-
tive droplets for a given amount of input DNA. It is important to note that the number of posi-
tive droplets was correlated with the number of probes, thus indicating an absence of
interference. The choice of primers and probes is also crucial; these must target small
sequences, since the average length of fetal DNA is about 140 bp [3, 17]. Hence, the amplicons
used in the present study did not exceed 75 bp in length. Furthermore, the target sequences are
Fig 2. Observed vs. theoretical chromosome ratios for mixtures of 0.5 ng/μL DNAwith a trisomy 21
DNA content of 0%, 5%, 10%, 25% and 50%. The solid black line corresponds to local polynomial
smoothing of the curve with 95% confidence intervals (dashed lines), and the solid gray line represents the
expected relationship.
doi:10.1371/journal.pone.0155009.g002
Digital PCR as a Non-Invasive Prenatal Test for Trisomy 21
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Fig 3. Box-and-whisker/Beeswarm plots of the distribution of chromosome ratios in the two groups
(upper plot), and the ROC curve for the chromosome ratio as a predictor of trisomy 21 (lower plot) for
samples exceeding the threshold for the number of positive PCRs. In the upper plot, the box displays the
Digital PCR as a Non-Invasive Prenatal Test for Trisomy 21
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located outside of regions affected by known, benign copy number variations. Lastly, it is essen-
tial to avoid interference by targeting genes that lack homology. Our PCR optimization experi-
ments showed that a combination of multiplexing and automated partitioning of template
DNA can be used for NIPT for trisomy 21.
In our validation study, we demonstrated that the multiplexed ddPCR approach provides
statistically significant discrimination between trisomic and euploid samples. The only false
negative sample came from a pregnant woman bearing a trisomic male fetus; consistently, the
ddPCR assay for SRY/RNaseP could not detect fetal DNA. This observation argues for system-
atic estimation of the fetal fraction as a pre-analytical quality check. Several researchers have
shown that this can be achieved by targeting a differentially methylated region within the
RASSF1A gene's promoter; the sequence is hypermethylated in placenta lymphocytes and
hypomethylated in maternal lymphocytes. Chan et al. made use of this methylation pattern to
perform a methylation-sensitive restriction enzyme digestion and then detect placenta-derived,
hypermethylated RASSF1A sequences in maternal plasma. They demonstrated that this univer-
sal marker is useful for the detection of false-negative results caused by low fetal DNA concen-
trations in maternal plasma [18]. We are now developing this step in order to further increase
the reliability of our ddPCR assay. Given that the threshold to be used in clinical applications
will depend on the fetal fraction, we are evaluating whether the estimation of the fetal fraction,
using a quantification based on the differential methylation of RASSF1A promoter between
maternal and fetal DNA, can be combined to the chromosomal ratio in order to further
strengthen the test.
Although we could demonstrate in this preliminary pilot study that it was possible to obtain
a significantly different chromosome 21/reference chromosome ratio between a group of
euploid and trisomic samples after stratification according to the karyotype result (Fig 3), a
larger cohort will obviously be paramount in order to determine an optimal threshold (for
maximizing sensitivity and minimizing the false positive rate) for prospectively classify the
samples. However, our ROC curve demonstrates that our assay already has the characteristics
of a very good screening test—far better than the current triple-test strategy. From a healthcare
point of view, an improvement in screening efficiency only makes sense if it can be made avail-
able to all pregnant women. A screening strategy based on this ddPCR assay would both
increase the number of screened, abnormal fetuses and decrease the number of invasive proce-
dures (and thus induced miscarriages). In contrast, if NIPT is restricted to at-risk women
(because of the high cost of MPS-based technologies), the rate of fetal loss would fall but the
screening performance would not improve. In this respect, the ddPCR assay's cost per sample
(between 30 and 40 euros, depending on the number of PCR reactions required to obtain 5900
positive droplets) and workflow match the requirements of a population-wide screening test.
The workflow is straightforward because a result can be obtained within a day. Up to 12 sam-
ples can be run at once. The test's efficiency and throughput could be increased further by auto-
mating the reaction mix preparation and droplet generation. The data analysis is very simple
and does not require intensive computation or large storage facilities. The equipment is also
relatively affordable, and easy to install and implement in routine laboratory practice. Lastly,
from an ethical point of view, this test is compatible with the large-scale screening of a low-
risk population of pregnant women because there is no longer any need to access sequence
information.
median [25th-75th percentiles] for the distribution; the whiskers indicate the data points no further than 1.5
times the interquartile range from the box; crosses represent the group means; data points are plotted as
open circles; n = 17 and 187 sample points for the trisomy 21 and normal group respectively. In the lower plot,
the AUROC is given with its 95% confidence interval(AUC: Area Under the Curve).
doi:10.1371/journal.pone.0155009.g003
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Because it has been demonstrated that all the fetal genome is entirely represented among
the circulating DNA [19], the choice of the reference chromosome should not be an issue.
Hence we selected for this proof of concept study the chromosome 18 as reference chromo-
some in order to open the field to the screening of both trisomy 21 and 18 at the same time.
We are aware of concerns regarding the frequency of trisomy 18 in confined placental mosai-
cism [20–22], but this event can result in a false positive for trisomy 18 not for trisomy 21
which is studied here. A false negative situation for trisomy 21 due to confined placental tri-
somy 18 is a priori not possible since these two conditions have never been observed concomi-
tantly. However, we validated our multiplex PCR system using chromosome 1 as the reference
chromosome and demonstrate that this system is valid whatever the chromosome tested but
the ratio threshold will probably differ according to the probes used.
This proof of concept study demonstrates that multiplex ddPCR is a promising approach for
NIPT for trisomy 21, which can be extended to the detection of other aneuploidies and large
copy number variations. Because MPS or MBM have already proven their efficiency in this pur-
pose, practical use of ddPCR in clinical setting will probably depend upon technical optimization
of the technology and on pricing evolution of MPS or MBM to make it (or not) available to all
pregnant women. Furthermore, further experiments will be necessary for trisomy 18 screening.
Supporting Information
S1 Fig. A two-dimensional representation of the fluorescence intensity obtained for plasma
DNA using the octoplex ddPCR assay. The y and x axes correspond to the FAM and VIC
intensities, respectively. Negative droplets (grey dots) and positive ones (blue dots for FAM
+ only, green dots for VIC+ only and brown for FAM+ and VIC+) are assigned as a function of
the FAM and VIC florescence amplitudes.
(TIF)
S2 Fig. Electrophoresis analysis, by the Agilent 2100 Bioanalyzer system, of an artificially
degraded genomic DNA using the Covaris ultrasonicator, in order to mimic the plasma
DNA degradation profile.
(TIF)
S3 Fig. Box and whisker plots of the distribution of chromosome ratios in the two groups
(upper plot) and the ROC curve for the chromosome ratio as a predictor of trisomy 21
(lower plot) for first trimester pregnancies samples. In the upper plot, the box displays the
median [25th-75th percentiles] for the distribution; the whiskers indicate the data points no fur-
ther than 1.5 times the interquartile range from the box; crosses represent the group means;
data points are plotted as open circles (n = 10) and sample points (n = 75) for the trisomy 21
and normal group respectively. In the lower plot, the AUROC is given with its 95% confidence
interval (AUC: Area Under the Curve).
(TIF)
S1 Table. Results of chromosomal ratios for mixtures of 0.5 ng/μL artificially degraded
DNA with a trisomy 21 DNA content of 0%, 5%, 10%, 25% and 50%.
(DOCX)
S2 Table. Validation study: the results of ddPCR on plasma DNA. k 21 and k ref are the
number of positive droplets for chromosome 21 and the reference chromosome, respectively. n
is the total number of PCRs. λ 21 and λ ref are the estimated mean number of copies per drop-
let, according to the Poisson distribution. NA = not available.
(DOCX)
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S3 Table. Results of ddPCR on a set of plasma DNA using chromosome 1 as a reference
chromosome.We used a set of three FAM TaqMan1 hydrolysis assays for the APP, BRWD1
and RUNX1 genes (Assays identities respectively: Hs01344980_cn, Hs03026207_cn and
Hs05550012_cn; Life Technologies, Carlsbad, CA, US) and three VIC TaqMan1 hydrolysis
assays for the ASTN1, FAF1 and PUM1 genes (Assays identities respectively: Hs05795637_cn,
Hs06521574_cn and Hs06604919_cn; Life Technologies, Carlsbad, CA, US). ddPCR protocol
was the same as described in the Materials and Methods section. k 21 and k ref are the number
of positive droplets for chromosome 21 and the reference chromosome, respectively. n is the
total number of PCRs. λ 21 and λ ref are the estimated mean number of copies per droplet,
according to the Poisson distribution.
(DOCX)
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